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Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71 S63engrafted. All trials utilized the 2 step approach. The MA
conditioning regimen was 12 Gy of TBI over 4 days. 2 MR
HSCT pts received a reduced intensity conditioning with
Fludarabine/Cytarabine and 2 Gy of TBI. Conditioning was
immediately followed by an infusion of 2 x 108 CD3+ cells/kg
donor T cells (step 1). CY 60 mg/kg/d x 2 was given starting
2 days after the T cell infusion. Tacrolimus and MMF were
begun on day -1. A CD 34 selected product was infused on
day 0 (step 2).
Both HI and MR showed equivalent early IR in all T-cell
subsets with no statistical differences between them. There
were no deaths from infections or GVHD. GVHD was
controlled in all cases with steroids and/or photopheresis.
Each group had 1mortality from regimen related toxicity. No
rejections or engraftment failures were observed. CMV
reactivation was higher in the HI group, with no CMV organ
disease. After a median follow up of 18 months (range 2-60),
both HI and MR HSCT had similar survival rates, 83% and 78%
respectively.
Using the same 2 step approach, which allows uniform T cell
dosing, comparable outcomes were seen in terms of IR,
signiﬁcant GVHD, incidence of regimen-related mortality
and survival in HI vs MR HSCT recipients, albeit with higher
CMV reactivation. The establishment of this "level playing
ﬁeld" in terms of non-relapse mortality, allows for future
inquiries which compare graft versus tumor effects between
the 2 donor sources with less confounding inﬂuences.LATE EFFECTS/QUALITY OF LIFE/PSYCHOSOCIAL ISSUES
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Background: It has been 20 years since the ﬁrst unrelated
cord blood transplant (CBT) and many CBTs that followed,particularly early on, were performed in young children.
Improved donor selection, management of transplant-related
complications, and supportive care have led to increasing
numbers of long-term survivors of CBT. Infants and young
children who undergo allogeneic CBT are at increased risk for
certain late effects due to organ immaturity at the time of
transplantation, particularly if radiation is used. Myeloablative
regimens using Busulfan (Bu) have been employed to elimi-
nate radiation exposure and associated consequences. In this
single center retrospective review, late effects in young
children receiving CBT following myeloablative, Bu-based
conditioning regimens are reported.
Methods: The records of 215 consecutive patients from 1993
to 2008 who received Bu containing conditioning regimens
for allogeneic CBT at< 2 years of age were reviewed. Of these,
105 patients who survived at least 5 years post-CBT were
identiﬁed. A database was created to capture information
regarding patient demographics, diagnosis, cord blood unit
(CBU) characteristics, graft-related outcomes, and incidence
and severity of organ system-speciﬁc late effects.
Results: Of the 182 patients who underwent CBT at least 5
years prior, 58% were alive at 5 years post-CBT (n ¼ 105).
Median time from transplant was 10.8 years (range 5.1e19.9
years). Sixty-four percent of these patients were male and
83% were Caucasian. Diagnoses included inherited metabolic
disease (58%, majority were Krabbe disease and Hurler
syndrome), leukemia (20%), immune deﬁciency (16%), bone
marrow failure/myelodysplastic syndrome (4%), and hemo-
globinopathy (2%). Median age at time of CBT was 1.04 years
(range 0.06-1.96 years). All patients received Bu containing
regimens. Most received Bu/Cyclophosphamide/ATG (71%) or
Bu/Melphalan/ATG (17%). CBUs were human leukocyte an-
tigen (HLA) matched at 4/6 (43%), 5/6 (45%), and 6/6 (12%). Of
the 112 patients who underwent CBT at least 10 years prior,
57 and 54% were alive at 5 and 10 years post-CBT, respec-
tively. There were no deaths after 10 years post-CBT. The
most commonly observed late effects included dental
problems, short stature, and pubertal delay/gonadal failure.
Pulmonary dysfunction was less common, and the majority
of cases were mild. We will describe the characteristics of
this cohort and where possible, compare these with existing
data regarding late effects after allogeneic transplantation
using TBI containing regimens.
Conclusions: This is the ﬁrst report of late effects of Bu-based
conditioning in a large cohort of patients who were very
young at time of CBT. These results will inform clinical care
and guidelines for long-term follow-up, as well as add to the
growing information regarding late effects of HSCT in general.62
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Background: Previous research suggests that chronic graft-
versus-host disease (cGVHD) is a risk factor for depressive
symptomatology among allogeneic hematopoietic cell
transplant (HCT) survivors. The extent to which coping
modiﬁes this risk is unknown, however.
Objective: The goal of the current study was to determine
whether coping strategies modify risk of depression among
patients with cGHVD.
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allogeneic HCT recipients, participants were assessed 90 days
post-transplant. Participants completed the Center for
Epidemiological StudieseDepression Scale, the Coping Re-
sponses Inventory focusing on coping with the disease and
its treatment, and the Lee Chronic Graft-Versus-Host Disease
Speciﬁc Symptom Scale. Descriptive, correlation and
moderation analysis were performed.
Results: The sample consisted of 105 participants (mean age
52, range 20-76, 42% female). A total of 28% of the sample
met criteria for clinically signiﬁcant depressive symptom-
atology. Univariate Spearman correlations indicated that
depression was associated with greater cGVHD severity as
well as the coping strategies of avoidance, acceptance and
resignation, emotional discharge (p values <.01). Problem
solving coping was associated with less depression (p¼.03).
Moderator analyses indicated that coping strategies signiﬁ-
cantly modiﬁed the risk of depression associated with
cGVHD. Speciﬁcally, cGVHDwas signiﬁcantly associated with
depression among patients who frequently used maladap-
tive coping strategies (i.e., avoidance, emotional discharge)
and rarely used adaptive coping strategies (i.e., positive
reappraisal, problem solving). In contrast, cGVHD severity
was not associated with depression in patients who
frequently used problem solving and infrequently used
avoidance and emotional discharge.
Discussion: Results from the current study suggest that
adaptive coping mitigates cGVHD as a risk factor for depres-
sion. These results highlight the importance of psychological
interventions to improve coping as a means to prevent or
reduce depressive symptomatology associated with cGVHD.
Funding: NCI K07 CA138499Table: Conditional probability of 10-yr outcomes in 1-year 2nd allo HCT





Overall survival 55 (44-65) 39 (31-48)
Non-relapse mortality 10 (5-17) 34 (26-42)
Relapse 34 (26-43) 32 (24-40)63
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Little is known about long-term outcomes in survivors of 2nd
allo HCT performed for patients who have relapsed following
a previous allo HCT. We analyzed outcomes of 1-year survi-
vors following 2nd allo HCT who were reported to the
CIBMTR between 1980 and 2009. Overall, 1285 patients
received a 2nd HCT for relapsed acute leukemia or myelo-
dysplastic syndromes; 325 1-year survivors were eligible for
this study (children¼146, adults¼179). Rate of 1-year sur-
vival was 35% for all pts. The corresponding rates for children
and adults were 30% and 46%. The majority of grafts (61%)
used the same donor for the 2nd transplant. The median age
at 2nd HCT was 9 (range: 1- 17) years and 38 (range 19-66)
years for children and adults, respectively. Myeloablative
(MA) regimenwas used in 89% for 1st and 62% for 2nd HCT in
children and in 79% and 45% of adults. 16% children and 32%
adults had a history of chronic GVHD prior to 2nd HCT. In the
two age groups, median time from 1st HCT to relapse was 14
mos and 18 mos, and median time from 1st to 2nd HCT was
17 mos and 24 mos, respectively. The Table shows the con-
ditional probability of 10-year outcomes. Chronic GVHD
developed in 43% and 75% children and adults following 2nd
HCT. Relapse was the major cause of death (43/56 for chil-
dren and 54/96 for adults, respectively). In proportional
hazard models, only disease status (relapse/progression)
prior to second HCT was associated with statistically signif-
icant higher risk for mortality (HR 1.71 (95% CI 1.22-2.38) vs.
remission; P<0.01). Other pre-transplant characteristics had
no impact on survival including age, interval between 1st
and 2nd HCT, chronic GVHD, 1st-2nd HCT donor pair, or
conditioning intensity for 2nd HCT. The CIBMTR collects in-
formation on selected late complications. The cumulative
incidence of developing at least one late effect for which data
were collected at 10-years following 2nd HCT was 63% in
children and 55% in adults. In children, notable late effects
were growth disturbance (10-year cumulative incidence after
2nd HCT 22%), cataracts (20%), gonadal dysfunction (16%), and
hypothyroidism (13%). In adults, cataracts (20%), avascular
necrosis (13%) and hypothyroidism (5%) were commonly re-
ported late effects after 2nd HCT. In summary,1-year survivors
of 2nd allo HCT for relapsed acute leukemia or MDS have
favorable long-term outcomes. Attaining remission prior to
HCT is the single favorable predictive factor for long-term
survival. Majority of late failures are due to relapse and late
effects are frequently encountered. Future trials focusing on
reducing risks of relapse and implementing systematic sur-
veillance for long-term toxicities are warranted.
